BioAtla BCAB
OTC BCAB
$1.65 +0.35 (+26.92%)
At close: Oct 2, 2026 · 4:00 PM EDT

BioAtla (BCAB) Gains from Sales and Divestitures (2022 - 2023)

Updated

BioAtla's Gains from Sales and Divestitures came in at -$185,000 for FY2025.

Analysis

BioAtla (BCAB) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends

Going back to FY2019, BioAtla's Gains from Sales and Divestitures data covers 5 years.

  • The FY2025 figure represents the lowest annual Gains from Sales and Divestitures in data going back to FY2019.
  • Per Business Quant, earlier years put Gains from Sales and Divestitures at -$2,000 in FY2023, -$13,000 in FY2022 and -$4,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 BioAtla 2.74 Mn 2.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,000.00
Dec 31, 2022 -7,000.00
API Access

BioAtla Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BCAB&period=max&api_key=YOUR_API_KEY